Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026
1. Novo Nordisk's Q4 2024 sales hit $12.25 billion, exceeding expectations. 2. Obesity care sales soared 91%, indicating strong market growth. 3. EPS rose 29% to $0.91, surpassing the consensus estimate. 4. Novo Nordisk plans Phase 3 trials for CagriSema in 2025. 5. Sales growth forecast for 2025 is 16% to 24%, below 2024 growth.